Brooklyn Immunotherapeutics Inc
NASDAQ:BTX
Brooklyn Immunotherapeutics Inc
Revenue
Brooklyn Immunotherapeutics Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
B
|
Brooklyn Immunotherapeutics Inc
NASDAQ:BTX
|
Revenue
$5.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Brooklyn Immunotherapeutics Inc
Revenue Breakdown
Breakdown by Geography
Brooklyn Immunotherapeutics Inc
Breakdown by Segments
Brooklyn Immunotherapeutics Inc
Total Revenue:
5.8m
USD
|
Subscription Revenue:
4.9m
USD
|
Other Revenue:
492k
USD
|
Hardware Revenue:
426k
USD
|
See Also
What is Brooklyn Immunotherapeutics Inc's Revenue?
Revenue
5.8m
USD
Based on the financial report for Dec 31, 2020, Brooklyn Immunotherapeutics Inc's Revenue amounts to 5.8m USD.
What is Brooklyn Immunotherapeutics Inc's Revenue growth rate?
Revenue CAGR 1Y
-71%
Over the last year, the Revenue growth was -71%.